Eli Lilly

Biologic Therapeutic Drugs: Technologies and Global Market Report 2024, with Company Profiles of Amgen, Abbive, Eli Lilly, Novartis and Glaxosmithkline - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Health, Pharmaceutical, Eli Lilly, Amgen, ESG, Geography, Vaccine, Patent, Medicine, Novartis, Environment, Cancer, Pharmaceutical industry

The "Biologic Therapeutic Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biologic Therapeutic Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The report also covers market projections through 2028, as well as key market players.
  • Estimate of the actual market size and revenue forecast, and a corresponding market share analysis by product type, therapeutic area and region.
  • Company profiles of major players within the industry, including Amgen, Abbive, Eli Lilly, Novartis and Glaxosmithkline

Sermonix Pharmaceuticals Announces MBC Alliance Membership, New ‘Discover ELAINE’ Website

Retrieved on: 
Monday, February 12, 2024
Eli Lilly, Therapy, Breast cancer, Fulvestrant, Neoplasm, Quality of life, MBC, Learning, Life, ESR1, Patient, Child, Mutation, Partnership

“Lasofoxifene, our lead investigational drug, has demonstrated both potential efficacy in combating metastatic breast cancer and potential benefit with respect to vaginal and sexual health.

Key Points: 
  • “Lasofoxifene, our lead investigational drug, has demonstrated both potential efficacy in combating metastatic breast cancer and potential benefit with respect to vaginal and sexual health.
  • The website and studies were named for Dr. Elaine Davidson Nemzer, the sister of Miriam Portman.
  • Davidson Nemzer was a brilliant and compassionate child psychiatrist whose life was cut short by mBC at the age of 47.
  • “It provides us with passion and purpose to help those suffering with metastatic breast cancer.”
    To learn more about Sermonix Pharmaceuticals and lasofoxifene, visit https://sermonixpharma.com .

Weekly Recap: 13 Press Releases You Might Have Missed

Retrieved on: 
Friday, February 9, 2024
Honey, Big Game, Database, Creativity, Love, Carbon footprint, Food, Cabin, Taste, Gap Inc., Hydrogen, OpenTable, Squarespace, PR Newswire, Humour, Friends, McDonald's, Automation, Joy, Harley-Davidson, Climate, Eli Lilly, Pain, News, In-flight entertainment, PACE, Water, Gap, SpaceX, SpaceX launch vehicles, Atmosphere, NASA, Head, Old Navy, Geography, Uniform, EVP, Culture, Pizza Hut, Ecosystem, Romantic, JOMO, Related, NERDS, Fox Corporation

NEW YORK, Feb. 9, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

Key Points: 
  • NEW YORK, Feb. 9, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire.
  • To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.
  • From the commercials to the food and beyond, catch up on all the Big Game press releases from PR Newswire before kickoff on Sunday.
  • These are just a few of the recent press releases that consumers and the media should know about.

Organizations Unite to Improve Brain Health

Retrieved on: 
Thursday, February 8, 2024
Well, Health, Workplace, Knowledge, Eli Lilly, Policy, Scorecard, Sleep deprivation, Hypertension, Life, Social isolation, Deficit spending, Organization, Dementia, Diabetes, Hearing loss, AARP, Shell, Senior, Risk, American Heart Association, Novo Nordisk, Longevity, Milken Institute, Obesity

This initiative brings together leaders from some of the biggest organizations in America to create environments that promote brain health for employees, communities, and consumers as brain health conditions rise, including Alzheimer’s and dementia.

Key Points: 
  • This initiative brings together leaders from some of the biggest organizations in America to create environments that promote brain health for employees, communities, and consumers as brain health conditions rise, including Alzheimer’s and dementia.
  • Among other action items, the Collaborative is working with HERO Health and Mercer to develop a Brain Health Best Practices Scorecard.
  • “We are excited to be working alongside so many innovative organizations in the Collaborative to advance practices and programs in the workplace and throughout communities at large to help optimize brain health,” said Sarah Lenz Lock, Senior Vice President for Policy and Brain Health and Executive Director of the Global Council on Brain Health.
  • For more information about the Business Collaborative for Brain Health and the Brain Health Best Practices Scorecard, click here .

Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, February 7, 2024
Extracellular matrix, Tech, Cell, Eli Lilly, AI, Phenotype, Biomarker, Patient, Fibroblast, Idiopathic pulmonary fibrosis, Drug discovery, Messenger, Myofibroblast, AbbVie, Disease, IPF, ADMET, Pharmaceutical industry

BERNARDSVILLE, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate.

Key Points: 
  • BERNARDSVILLE, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anima Biotech, the Tech.Bio leader bringing AI to mRNA biology, announced today positive preclinical data of its lung fibrosis candidate.
  • This drug operates through a novel mRNA biology mechanism of action, opening new avenues for treating Idiopathic Pulmonary Fibrosis (IPF) patients.
  • Utilizing its mRNA Lightning™ Platform, Anima has successfully identified a preclinical candidate operating through a novel mRNA biology mechanism of action, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts.
  • By inhibiting myofibroblasts' deposition of extracellular matrix, this candidate demonstrates substantial potential in mitigating fibrotic diseases.

GAMCO Investors, Inc. Reports Results for the Fourth Quarter and Year Ended December 31, 2023

Retrieved on: 
Tuesday, February 6, 2024
Catalysis, ServiceNow, Weight loss, Growth, Apple, Eli Lilly, GABF, CrowdStrike, LOPP, Mag, Funding, AUM, ETF, PWM, Investment, Artificial intelligence, Net, Meta Platforms, Microsoft, CIO, Columbia Business School, Depression, CFA, Cryptocurrency

(b) Includes $227, $230, and $223 of 100% U.S. Treasury Money Market Fund AUM at December 31, 2023, September 30, 2023, and December 31, 2022, respectively.

Key Points: 
  • (b) Includes $227, $230, and $223 of 100% U.S. Treasury Money Market Fund AUM at December 31, 2023, September 30, 2023, and December 31, 2022, respectively.
  • Assets under management on December 31, 2023 were $31.1 billion, an increase of 6.5% from the $29.2 billion on September 30, 2023 reflecting general market trends.
  • Howard Ward, CFA, the CIO of Growth Investing, commented on The Gabelli Growth Fund’s 2023 performance: “The stars aligned for growth stocks in 2023.
  • Assets under management in SICAV on December 31, 2023 were $631 million, an increase from the $622 million on September 30, 2023.

Gallant Therapeutics Adds Animal Health Executive Aaron Schacht to Board of Directors

Retrieved on: 
Tuesday, February 6, 2024
Gallant, SAN, Growth, Eli Lilly and Company, Eli Lilly, Research, Kindred, FDA, Biotechnology, Disease, Therapy, Boehringer Ingelheim, Novartis, DVM, Health, Pet, Synthetic biology

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the addition of Aaron Schacht to its Board of Directors.

Key Points: 
  • SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the addition of Aaron Schacht to its Board of Directors.
  • "The field of animal health is hungry for innovative solutions to address our pets' health concerns,” said Aaron Schacht.
  • Mr. Schacht led several strategic acquisitions, including Bayer Animal Health, Aratana Therapeutics, and Kindred Biosciences.
  • Additionally, he integrated R&D capabilities and pipelines from Novartis Animal Health, Boehringer Ingelheim pet vaccines, Bayer Animal Health, Aratana, Prevtec, and Kindred.

PDA Announces Collaboration with the U.S. FDA Concerning Services for Pharma Compounders

Retrieved on: 
Monday, February 5, 2024
Online, Partnership, Policy, Interest group, Human services, Research institute, Curriculum, Eli Lilly, Patient, FDA, Publication, PPD, PDA, Food, Name, Virtual, Pharmacy, Conference, CGMP, Hospital, Pharmaceutical industry

BETHESDA, Md., Feb. 5, 2024 /PRNewswire-PRWeb/ -- PDA is proud to announce a new four-year collaboration with the U.S. Food and Drug Administration's (FDA) Compounding Quality Center of Excellence, established to support outsourcing facilities and related stakeholders in their efforts to provide high-quality drugs for patients who need them. Through the partnership, PDA will expand its current training course opportunities for professionals in the outsourcing facility and compounding community and establish an ongoing interactive in-person and virtual interest group forum.

Key Points: 
  • Michael Porter has joined the PDA Education team to oversee the deployment of the new training courses and to liaise with the FDA.
  • He brings a wealth of experience and expertise to PDA, having worked previously for Pharmatech Associates, a USP Company, PPD, and Eli Lilly.
  • The training courses will take advantage of the entire gambit of multimedia modalities, including in-person, virtual, and self-guided online training courses.
  • This new interest group will launch at PDA Week 2024 followed by virtual meetings starting in April and May.

Mallinckrodt Announces Board of Directors and Leadership Updates

Retrieved on: 
Friday, February 2, 2024
Public, Genetics, Eli Lilly and Company, ExxonMobil, CFO, Eli Lilly, Patient, Teva Pharmaceuticals, Marketing, Executive Committee, Barr Pharmaceuticals, Sigi, Ecology, Morgan Stanley, Amneal Pharmaceuticals, Aspen Pharmacare, ViiV Healthcare, Employment, Bausch Health, GSK plc, The Company, Thermo Fisher Scientific, Therapy, Chairperson, KKR, Engineering, Management

DUBLIN, Feb. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately. Mr. Bisaro has also been reappointed to his previous role as Board Chair. In addition, the Company announced that Siggi Olafsson has entered into a new employment agreement and will continue in his roles as Mallinckrodt's President and Chief Executive Officer and a member of the Board.

Key Points: 
  • Four Directors Added to Board Bring Seasoned Experience in Pharmaceuticals, Healthcare, Finance and Operations
    Siggi Olafsson Will Continue as President, CEO and Board Member
    DUBLIN, Feb. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately.
  • Our ability to attract these accomplished directors is a testament to what we have achieved so far and the opportunities ahead for Mallinckrodt."
  • Select professional highlights of Mallinckrodt's new directors include:
    Paul Bisaro is a healthcare industry leader with more than three decades of leadership experience at generic and branded pharmaceutical companies.
  • With the appointment of Messrs Bisaro, Hussain and Wheeler and Ms. Dorton, Mallinckrodt's Board comprises seven directors.

Summary of opinion: Retsevmo, 25/01/2024 Positive

Retrieved on: 
Sunday, February 4, 2024
Marketing, European Commission, Selpercatinib, Civil service commission, MTC, Committee, CHMP, Medication package insert, Iodine, RET, Eli Lilly, NSCLC

On 25 January 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.

Key Points: 
  • On 25 January 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.
  • The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V.
  • The CHMP adopted a new indication to include treatment of adults and adolescents with RET fusion-positive thyroid cancer that is radioactive iodine-refractory.
  • 1 New text in bold